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Abstract
Renal cell carcinoma (RCC) occurs in 2-4% of patients with tuberous sclerosis complex (TSC).
Previous reports have noted a variety of histologic appearances in these cancers, but the full
spectrum of morphologic and molecular features has not been fully elucidated. We encountered 46
renal epithelial neoplasms from 19 TSC patients and analyzed their clinical, pathological and
molecular features, enabling separation of these 46 tumors into three groups. The largest subset of
tumors (n=24) had a distinct morphological, immunological and molecular profile, including
prominent papillary architecture and uniformly deficient SDHB expression prompting the novel
term “TSC-associated papillary RCC.” The second group (n=15) was morphologically similar to a
hybrid oncocytic/chromophobe tumor (HOCT) while the last 7 renal epithelial neoplasms of group
3 remained unclassifiable. The TSC-associated papillary RCCs (PRCC) had prominent papillary
architecture lined by clear cells with delicate eosinophilic cytoplasmic thread-like strands that
occasionally appeared more prominent and aggregated to form eosinophilic globules. All 24
(100%) of these tumors were the International Society of Urological Pathology (ISUP) nucleolar
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grade 2 or 3 with mostly basally located nuclei. Tumor cells from 17 of 24 TSC-associated PRCC
showed strong, diffuse labeling for CA-IX (100%), CK7 (94%), vimentin (88%), CD10 (83%),
and were uniformly negative for succinate dehydrogenase subunit B (SDHB), TFE3 and AMACR.
Gains of chromosomes 7 and 17 were found in 2 tumors, whereas chromosome 3p deletion and
TFE3 translocations were not detected. In this study, we reported a sizable cohort of renal tumors
seen in TSC and were able to identify them as different morphotypes which may help to expand
the morphologic spectrum of TSC-associated RCC.
Keywords
Renal cell carcinoma; tuberous sclerosis complex; succinate dehydrogenase; hybrid oncocytic/
chromophobe tumor; immunohistochemistry; molecular genetics
Introduction
Tuberous sclerosis complex (TSC) is an autosomal dominant genetic disorder. Once
characterized by epilepsy, developmental delay and facial angiofibromas, the syndrome can
affect nearly every organ system to varying degrees, including the brain, skin, heart, lungs,
and kidneys. The incidence of TSC is estimated to be 1 in 6000 to 1 in 10000 persons
worldwide.(1) A disease-causing mutation in either TSC1 (Chromosome 9q34), encoding
the protein hamartin, or in TSC2 (chromosome 16p13), encoding the protein tuberin, can be
identified in most patients with TSC. These proteins act together as tumor suppressors and
are components of the mTOR (mammalian target of rapamycin) signaling pathway.(2)
The kidney is affected in approximately 80-85% of individuals with TSC and renal
involvement has been reported as the leading cause of death in TSC patients.(1, 3) Renal
manifestations in TSC include angiomyolipoma (AML), simple and complex cysts and renal
epithelial neoplasms, including oncocytoma and renal cell carcinoma (RCC). With the
increasing awareness and surveillance, RCCs are more commonly reported, both in adults
and children with TSC. An estimated incidence of RCC in TSC patients is reported to be
2-4%, higher than the estimated incidence in the general population (4), and often occurs in
children and young adults.(5, 6)
A variety of histologies of TSC-associated RCCs have been reported, including clear cell,
papillary, chromophobe and unclassified RCC, as well as benign renal oncocytoma.(5, 7-11)
However, the full spectrum of morphologic features has not yet been well elucidated due to
limited amounts of pathologic material in some cases, and overlapping features with fat-poor
angiomyolipomas. Furthermore, the immunophenotype of TSC-associated RCC has not
been studied using modern antibody repertoires.(5, 11-13) Few RCCs in TSC patients have
been reported to have co-expression of renal tubular and melanocytic markers such as
HMB-45, and unlikely represented Xp11 translocation RCC, which further added to the
tumor heterogeneity identified in these patients(5, 14). Absence of von Hippel-Lindau
(VHL) gene mutation and loss of heterozygosity (LOH) was reported in 6 clear cell TSC-
associated RCCs (13), in contrast to cytogenetic findings in sporadic RCC of the general
non-TSC population, suggesting that clear cell TSC-associated RCC develops independently
of canonical pathways.
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To better understand and characterize TSC-associated RCCs, we have studied 46 renal
epithelial tumors from 19 TSC patients. We performed immunohistochemical and
cytogenetic analysis, and describe the morphological findings among this group of tumors.
We sought to investigate whether any particular histologic type of renal cell neoplasm was
more frequently found in TSC, and whether any distinct histologic features correlated with
genetic abnormalities and/or immunoprofiles. We found that a sizeable subset of TSC-
associated renal tumors in this series, 39 of 46 (85%), seen in 17 of 19 (90%) TSC patients,
had distinct features as described below.
Materials and Methods
Patient and Tumor Specimens
All 19 patients were treated at the authors' institutions with a clinical diagnosis of TSC as
defined by the 1998 Tuberous Sclerosis Complex Consensus Conference.(15, 16)
Tumors were provided by the Massachusetts General Hospital, Boston, MA (n=9), Brigham
and Women's Hospital, Boston, MA (n=5), University of Massachusetts Medical School,
Worcester, MA (n=1), University of Michigan Health System, Ann Arbor, MI (n=1),
University of California, San Francisco, CA (n=1), Children's Memorial Hospital, Warsaw,
Poland (n=1), and Peking Union Medical College Hospital, Beijing, China (n=1). The
original pathologists varied in their interpretation of the histological findings: 1 was
considered to be oncocytoma, 3 were considered to be papillary RCC (one type 1 and two
type 2), 5 were considered to be clear cell RCC, 5 were considered to be chromophobe RCC,
and 32 were considered to be RCC, unclassified.
The patient demographics, clinical history, and follow-up details were obtained from clinical
records. This study was approved by the human study committees at each hospital. The
gross findings, including the number and size of the tumors, and laterality, were noted from
the pathology reports. All 46 tumors assessed here were formalin-fixed and paraffin-
embedded. Four μm sections of each tumor with accessible tissue were obtained for
hematoxylin and eosin stain, immunohistochemistry and FISH analysis. Histologic subtypes
of RCCs were reviewed and reclassified according to criteria proposed in the 2004 World
Health Organization (WHO) classification of neoplasms of the kidney and International
Society of Urological Pathology Vancouver Classification of Renal Neoplasia (17) and
evaluated for the International Society of Urological Pathology (ISUP) nucleolar grade.(18)
The tumors that morphologically did not fit the criteria for the usual common renal cell
neoplasms were initially assigned the designation of unclassified RCC, according to the
above mentioned classification system. Attempts were made later to group such tumors into
more definitive categories if any consistent morphologic and/or immunohistochemical
features were observed.
Immunohistochemistry
At least 1 formalin-fixed, paraffin-embedded tissue block from each available tumor was
selected for immunohistochemical analysis. Multiple markers beneficial in discriminating
different subtypes of RCC were used: CK7 (Dako, Carpinteria, CA; clone OV-TL 12/30; 1:3
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dilution); CA-IX (Novus Biologicals, Littleton, CO; Clone 2D3; 1:5000 dilution); CD10
(Leica, Buffalo Grove, IL; clone 56C6; prediluted); AMACR/P504S (Dako; Clone 13H4;
1:300 dilution); RCC Ma (Dako; clone 5PM314; 1:50 dilution); CD117 (Cell Marque,
Rocklin, CA; clone YR145; prediluted); PAX8 (Cell Marque; rabbit polyclonal; 1:50
dilution); HMB45 (Leica; clone HMB45; prediluted); vimentin (Leica; clone SRL33;
prediluted); SDHB (Abcam Inc, Cambridge, MA; clone 21A11AE7; 1:1000 dilution), TFE3
(Cell Marque; clone MRQ-37; prediluted).
Immunohistochemistry was performed using the Leica Bond platform (Leica, Buffalo
Grove, IL, USA). Sections were deparaffinized on the automated stainer using Bond Dewax
Solution (Leica) and rehydrated through graded ethanol solutions to distilled water. Antigen
retrieval was achieved by heating sections in Citrate Based Solution (pH 6.0, Leica) for
CK7, CA-IX, and HMB45, or EDTA Based Solution (pH 9.0, Leica) for TFE3, AMACR,
CD10, vimentin, CD117, PAX8, and SDHB. Bound antibodies were localized using
Polymer Refine Kit (Leica, Buffalo Grove, IL), or Ultra Vision LP Detection System HRP
Polymer (Thermo Scientific, Fremont, CA). Diaminobenzidine (3, 3′-diaminobenzidine) was
used as the chromogen and hematoxylin was used as a counterstain. Positive and negative
controls were stained concurrently and showed appropriate immunostaining.
The extent of immunohistochemical staining was evaluated microscopically. The percentage
of tumor cells showing a positive reaction was estimated and, when appropriate, the staining
pattern was documented (membranous, cytoplasmic, apical, granular cytoplasmic, etc.). The
interpretation of immunoreactivity for TFE3 and SDHB were evaluated as previously
described.(19-22) SDHB stain was considered negative when all tumor cells showed diffuse
negative staining compared to the adjacent, normal renal tubular cells showing strong
positive staining. SDHB immunohistochemistry was applied on tumors with multiple blocks
to confirm the negative results presented in the representative section. SDHB
immunohistochemistry was repeated when tumor cells showed negative labeling in the
absence of adjacent normal kidney parenchyma (internal positive control). SDHB
immunohistochemistry was also performed on a limited number of cases of clear cell,
papillary and chromophobe RCC under the same conditions and were used as positive
controls. Other stains were graded as negative (0% cells positive), -/+ (1%-25%), +
(26%-50%), ++ (51%-75%), +++ (76%-100%).
Hale staining
Hale colloidal iron staining (Muller–Mowry modification) was performed in all HOTC
cases. The staining pattern was evaluated as negative, diffuse cytoplasmic or apical.
Fluorescence In Situ Hybridization
For patients with available tissue, at least 1 formalin-fixed, paraffin-embedded tissue block
was selected for fluorescence in situ hybridization (FISH).
FISH analyses were performed as described previously.(22-24) Briefly, a hematoxylin and
eosin-stained slide from each block was examined to identify areas containing tumor cell
clusters for cell counting. Multiple tissue sections 4 μm in thickness were prepared from
formalin-fixed paraffin-embedded tissue blocks. The slides were deparaffinized with 2
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washes of xylene, 15 minutes each, and subsequently washed twice with absolute ethanol,
10 minutes each, and then air dried in a fume hood. Next, the slides were treated with
0.1mM citric acid (pH 6.0) (Zymed, South San Francisco, CA) at 95 °C for 10 minutes,
rinsed in distilled water for 3 minutes, followed by a wash of 2×standard saline citrate (SSC)
for 5 minutes. Digestion of the tissue was performed by applying 0.4mL of pepsin (5 mg/mL
in 0.1N HCl/0.9 NaCl) (Sigma, St Louis, MO) at 37 °C for 40 minutes. The slides were
rinsed with distilled water for 3 minutes, washed with 2×SSC for 5 minutes, and air dried.
Centromeric chromosome enumeration probes (CEP) were utilized for chromosome 3
(CEP3, Orange), chromosome 7 (CEP7, Green), and chromosome 17 (CEP17, Orange) from
Vysis (Downers Grove, IL). FISH for chromosomes 7 and 17 was performed with
centromeric α-satellite DNA probe cocktail containing CEP7 and CEP17. Deletion of
chromosome 3p was assessed using a probe cocktail containing centromeric α-satellite DNA
probes for CEP3 (Spectrum Orange) and the subtelomeric probe for 3p25 (3pTel25,
Spectrum Green, Vysis). Assessment of TFE3 translocation was using an Interphase Break-
apart FISH assay with the 2 DNA probes.(22) Probes CEP7-CEP17 were diluted with
tDenHyb1 in a ratio of 1:100 and probes CEP3-3p25, TFE were diluted with tDenHyb 2
(Insitus, Albuquerque, NM) in a ratio of 1:100 and 1:25, respectively. The diluted probe (5
μL) was applied to each slide in reduced light conditions. The slides were then covered with
a 22×22-mm cover slip and sealed with rubber cement. Denaturation was achieved by
incubating the slides at 83 °C for 12 minutes in a humidified box and hybridization at 37 °C
overnight. The cover slips were removed, and the slides were washed twice with 0.1×SSC/
1.5M urea at 45 °C (20 minutes for each), followed by a wash with 2×SSC for 20 minutes,
and with 2×SSC/0.1% NP-40 for 10 minutes at 45 °C. The slides were further washed with
2×SSC at room temperature for 5 minutes. The slides were air dried and counterstained with
10mL 4, 6-diamidino-2-phenylindole (Insitus, Albuquerque, NM), covered with cover slips,
and sealed with nail polish.
FISH Evaluation
The slides were examined using a Zeiss Axioplan 2 microscope (Zeiss, Gottingen,
Germany) with the following filters (Chroma, Brattleboro, VT): SP-100 for DAPI, FITC
MF-101 for Spectrum Green, and Gold 31003 for Spectrum Orange. The images were
acquired with a charged coupled device camera and analyzed with MetaSystem Isis
Software (MetaSystem, Belmont, MA). Four sequential focus stacks with 0.4μm intervals
were acquired and then integrated into a single image to reduce thickness-related artifacts.
The method of analysis was partially described previously.(22, 25) In brief, for each slide, a
minimum of 100 tumor cell nuclei were examined under fluorescence microscopy at 1000×
magnification. Only nonoverlapping tumor nuclei were evaluated. Non-neoplastic renal
cortex was examined as an internal control. Definitions of chromosomal trisomy of
chromosomes 7 and 17 were based on the Gausian model and were related to the non-
neoplastic controls. The cutoff values for each probe were set at mean plus 3 SDs (mean+3
SD) of the control values.(26, 27) The cutoff value for 3p deletion was defined as a 3p25/
CEP3 ratio of ≤0.7, as previously described.(24, 28, 29) A TFE3 fusion result was reported
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when ≥10% of the tumor nuclei showed the split-signal pattern, based on other
commercially available break-apart FISH assays and TFE3 break-apart FISH assays.(30)
Results
The clinicopathologic characteristics of 46 TSC-associated RCCs are summarized in Table
1. There was a predominance of female patients (male-to-female ratio 1: 2). Mean age at the
first diagnosis of a renal tumor was 30 years (range from 7-59 y). Three patients underwent
biopsy, two chose conservative management, and one declined surgical intervention and has
since died. Four patients underwent radical nephrectomy and 12 had partial nephrectomy.
Follow-up data was available for 14 of 19 (74%) patients with a mean follow-up period of
48 months (range from 3-147 mo). One patient had regional lymph node metastasis at
presentation (patient 6); she has remained free of distant metastasis but has since developed
new bilateral renal neoplasms in her most recent surveillance imaging. All other treated
patients are alive with neither recurrence nor metastasis.
The average tumor size was 2.9 cm (range 0.1 – 22 cm). Fourt-eight percent of the tumors
were ISUP grade 2, while ISUP grade 1, 3 and 4 were 6%, 44% and 2%, respectively. Eight
of the 19 patients (42%) had multiple renal tumors (2-15) and 5 of 19 patients (26%) had
bilateral neoplasms. Of 5 patients with bilateral tumors, 2 had synchronous bilateral lesions
and 3 had their contralateral tumor(s) diagnosed 1, 5 and 11 years after the initial
nephrectomies. Concurrent, multiple renal angiomyolipomas, microscopic or macroscopic,
were found adjacent to the tumors in 56% of patients and cystic changes were observed in
56% of tumors.
The gross tumor appearance from 14 of 17 patients by partial or radical nephrectomy was
noted to be well-circumscribed, and occasionally cystic. Eight tumors were described as
encapsulated. The cut surface varied and was described as yellow, tan, red-brown,
hemorrhagic, or variegated. No gross tumor necrosis was reported.
The combined morphologic, immunohistochemical, and cytogenetic approaches allowed us
to subclassify these 46 tumors into three groups. The largest subset of tumors comprised of
24 neoplasms, and was termed TSC-associated papillary RCC. The second group contained
15 renal tumors morphologically similar to a hybrid oncocytic/chromophobe tumor (HOCT).
The last group of 7 renal epithelial neoplasms remained unclassifiable (Table 2).
TSC-associated Papillary RCC
Ninety-one percent of 24 group one tumors were microscopically circumscribed by fibrous
stroma of variable thickness. On low power, a complex branching papillary architecture was
observed in 75% of the tumors (18/24) (Figure 1A, 1C and 2A). In the remaining 6 tumors,
papillary architecture was present focally, appearing as small blunt papillae tufting into the
lumen (Figure 4E). One of these tumors (patient 7, tumor 12) exhibited an overwhelmingly
nested growth pattern (Figure 4A-4C), whereas 5 others, all from patient 8, showed a
primarily solid growth pattern (Figure 4D-F). Patient 8 had 10 additional predominantly
papillary tumors, similar to those displayed in Figures 1 and 2. These 15 tumors from patient
8 showed several growth patterns (solid, compact nested or papillary) that merged with each
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other (Figure 4D-E). Cystic change was commonly present (13/24), usually as microcysts
(Figure 1E). The cells lining the cysts were morphologically similar to those in the rest of
the tumor. Other architectural patterns, including acinar, tubular, and alveolar patterns, were
observed in varying proportions.
Cytologically, all except one tumor were predominantly composed of large clear cells with
voluminous cytoplasm. Cells with finely granular, eosinophilic cytoplasm were focally
present in 14 of 24 tumors. Tumor cells with clear cytoplasm were admixed with tumor cells
with eosinophilic cytoplasm without forming large geographic aggregates of one cell type
(Figure 1F). On high power, the clear cytoplasm often contained delicate thread-like
eosinophilic strands that occasionally appeared more prominent and aggregated to form
eosinophilic globules, a unique and consistent finding in all 24 of the tumors (Figure 1B,
1D, 2B, 4C and 4F). Cell borders were largely discrete, especially in clear cell areas,
irrespective of the architecture. Fifty-four percent of the tumors were ISUP grade 2, and the
remaining 46% of tumors were ISUP grade 3. The nucleus was round to oval to mildly
irregular, positioned either basally or centrally. Nuclear morphology was quite
homogeneous in clear cells but larger nuclei with prominent nucleoli were easily identified
in cells with eosinophilic cytoplasm. Mitotic figures were rare. Psammoma bodies/
calcifications were absent from all tumors. Foamy histiocytes were occasionally present in
cyst fluid, but not in the core of the papillae.
All tumor parenchyma were surrounded by hyalinized stroma, which sometimes showed
myxoid change (Figure 1E, 2A and 4D). Focal hemorrhage and necrosis occurred in one
tumor removed shortly after embolization treatment (patient 7, tumor 12).
Only patient 6 had pathologically confirmed metastasis to 3 of 8 peri-aortic lymph nodes
(the largest metastatic node was 1.3 cm) that were resected synchronously with the kidney
tumor. The morphologic features of the nodal metastasis resembled the kidney tumor.
Seventeen of 24 group 1 renal tumors had adequate tissue for immunohistochemical
analyses. Results of immunohistochemistry evaluation are displayed in Table 3. SDHB
protein expression was absent in all 17 tumors studied (Figure 2F, 3A-F, 4I). Negative
SDHB labeling was interpreted only when the tumor cells showed diffuse negative staining
and the adjacent normal renal tubular cells showed positive granular cytoplasmic staining.
CK7 expression was strongly and diffusely positive in almost all tumors (17/18) (Figure 2C,
4G) and all CK7-expressing tumors exhibited predominantly papillary growth. The only
tumor (tumor 12) showing focal CK7 expression (5%) was composed of nested clear to
eosinophilic cells with rare papillary structures (Figure 4A-C). Unlike sporadic papillary
RCC, these TSC-associated tumors completely lacked staining for AMACR. CA-IX
membranous staining was diffusely positive in all tumors, resembling clear cell RCC (Figure
2D, 4H). CD10 staining was positive in all cases, mostly strong, and diffuse (Figure 2E),
although weak and/or focal positivity for CD10 was seen in three tumors displaying a
primarily solid growth (patient 8). Vimentin and PAX8 were consistently positive in a
majority of tumors (15/17 and 15/15, respectively). All tumors studied were negative for
TFE3, HMB45, RCC Marker and CD117.
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In summary, tumors within this group showed an immunoprofile distinctly different from
any existing renal neoplasm subtype, which is summarized as: SDHB-/TFE3-/ RCC Ma-/
vimentin++/ CK7++/AMACR-/CA-IX++/CD10++.
FFPE blocks from 16 of these group 1 tumors were sectioned and analyzed by FISH, as
summarized in Table 3. None of the 16 tumors showed evidence of chromosome 3p
deletion. Two neoplasms (tumor 12 and 28) showed gains of chromosomes 7 and 17. None
of the tumors showed evidence of a TFE3 gene fusion by break-apart FISH assay.
Hybrid Oncocytic/Chromophobe Tumor (HOCT)
Fifteen of the 46 (33%) renal epithelial neoplasms displayed morphologic characteristics of
both an oncocytoma and chromophobe RCC, albeit in varying amounts, similar to a hybrid
oncocytic/chromophobe tumor (HOCT). There were two main histologic patterns identified
in these neoplasms. The first pattern, displayed in 5 of 15 (33%) HOCT tumors, was
comprised of polygonal tumor cells with abundant eosinophilic cytoplasm and centrally
placed, round nuclei, resembling an oncocytoma, with perinuclear cytoplasmic clearing or
halos, similar to chromophobe RCC (tumor 7, 9, 36, 42, 45) (Figure 5A-B). The second
contained a mosaic pattern, identified in 5 of 15 (33%) HOCT tumors, in which there was
admixing of areas with features characteristic of oncocytoma and chromophobe RCC (tumor
29, 30, 35, 43, 44) (Figure 5C), respectively. The 5 remaining tumors that did not exhibit
either of the two predominant histologic patterns, demonstrated various combinations of
morphologic features of the two neoplasms. Four of the 5 tumors contained a nested and
tubular architecture with cells comprised of abundant eosinophilic cytoplasm typical of an
oncocytoma with more irregular, folded or raisinoid nuclei, a quality of chromophobe RCC
(Figure 5D) (tumor 1, 37, 39, 41, 46).
The immunoprofile and FISH results of the tumors from this group are reported in Table 3.
In general, the tumors were reactive for PAX8, CD117 and CD10, and negative for TFE3,
HMB45, and CA-IX. Immunostaining with vimentin, RCC and AMACR were variable. All
of the tumors had preserved SDHB immunoreactivity. None of the tumors revealed
aberrations in chromosomes 3p, 7, or 17. In addition, a TFE3 translocation was not observed
in any of the tumors.
Unclassified RCC
A small subset of RCCs (n=7) contained morphologic and/or architectural patterns that did
not readily fit into any of the World Health Organization classification of RCC subtypes.
Therefore, they were categorized as unclassified RCCs (Figure 6).
Tumors 4, 5 and 6 from patient 4 displayed a variety of morphologies. Tumor 4 contained
tubules and papillae lined by cells with abundant eosinophilic cytoplasm with centrally
placed round nuclei and prominent nucleoli intermixed with moderate amounts of
inflammatory infiltrate (Figure 6A). Immunohistochemically, it was positive for vimentin,
RCC Ma, CD10 and AMACR, and negative for CK7, CA-IX and CD117. Tumor 5
contained a papillary architecture lined by a single layer of cuboidal cells with clear to
eosinophilic cytoplasm, and small round nuclei (Figure 6B). Immunohistochemically it was
positive for vimentin, RCC Ma, CK7 and AMACR and negative for CD10, CA-IX and
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CD117. Tumor 6 contained a papillary architecture lined by both clear to eosinophilic
cytoplasm and round nuclei (Figure 6C) with an immunoprofile that was positive for
vimentin, RCC Ma, and AMACR and negative for CK7, CD10, CA-IX and CD117.
Both tumors 32 (Figure 6E) and 34 (Figure 6F) from patient 11 were well- circumscribed
and composed of cuboidal cells with densely eosinophilic cytoplasm and oval to mildly
irregular nuclei. The neoplastic cells were arranged in either compact nests or small tubules.
Foamy macrophages were commonly seen in the lumen of the tubules or within the stroma.
The immunoprofiles of these two tumors were: vimentin-/RCC-/CK7-/CD10+/CA-IX-/
AMACR++/PAX8-.
Tumor 33 (Figure 6D) also from patient 11 was well-circumscribed, composed of sheets of
cells with fluffy eosinophilic cytoplasm and small uniform nuclei with inconspicuous
nucleoli. The tumor cells only showed diffuse positive immunoreactivity for CA-IX and
were negative for all the other markers in the immunohistochemical panel.
Tumor 40 (Figure 6G-I) from patient 17 was composed of cuboidal cells with indistinct cell
borders, arranged in compact nests and separated by abundant sinusoidal vasculature. The
cytoplasm was oncocytic with a granular and vacuolated quality. Nuclei were centrally
placed, round to oval in shape and displayed finely granular chromatin and small nucleoli.
The immunohistochemical profiles and morphologic features of these neoplasms did not
readily fit into any of the WHO renal cell carcinoma classifications.
Material was available for immunohistochemistry from 7 and FISH from 6 of the tumors in
this group. Results are summarized in Table 3. In brief, all tumors were negative for TFE3
and HMB45. Preservation of SDHB by immunohistochemistry was also present.
Immunohistochemical staining for the other markers showed variable patterns. There were
no aberrations identified in chromosomes 3p, 7 or 17. Additionally, no TFE3 gene fusions
were detected.
Discussion
Whereas most renal cell carcinomas (RCCs) occur sporadically, 3-5% are associated with
hereditary syndromes. To date, there are 10 well-defined hereditary renal cancer (HRC)
syndromes, including Von-Hippel Lindau (VHL) disease, hereditary papillary RCC,
hereditary leiomyomatosis-RCC, Birt-Hogg-Dubé (BHD) syndrome, and tuberous sclerosis
complex (TSC), among others.(31) Homogenous tumors are seen in some RCC syndromes,
such as clear cell RCC in VHL disease and type 1 papillary RCC in hereditary papillary
RCC. Heterogeneous tumors are reported in BHD syndrome.
Renal cell carcinoma is a rare renal manifestation in TSC patients, with an estimated
incidence of 2-4%, which is nonetheless higher than in the general population.(4) Although
renal carcinomas have been increasingly found in TSC patients, their histological and
molecular characteristics remained poorly defined. The reported histological appearance of
TSC-associated RCCs is heterogeneous. Most have been identified as clear cell RCCs, but
other reported types include papillary, chromophobe, and unclassified RCC as well as
benign renal oncocytoma.(5, 7-11)
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In this study, we first describe 24 renal epithelial neoplasms from 9 TSC patients for their
morphological, immunophenotypic and cytogenetic features. Morphologically, these tumors
displayed a prominent papillary architecture lined predominantly by cells with clear
cytoplasm. Prominent complex, branching papillary structures are a hallmark of these
tumors. Another unique feature is the delicate eosinophilic cytoplasmic thread-like strands,
not seen in other types of RCC. Immunologically, all studied neoplasms were consistently
positive for CK7, vimentin, CD10 and carbonic anhydrase IX (CA-IX), with no
immunoreactivity for SDHB, TFE3, AMACR, and RCC Marker. This immunological
profile is distinct from all other known RCC subtypes.
Each of the four known RCC subtypes--clear cell RCC, type 1 papillary RCC, Xp11
translocation RCC, clear cell (tubulo) papillary RCC--share some morphological and
immunological features with the TSC-associated papillary RCC (Table 4).
For example, all the TSC-associated PRCCs consistently displayed reactivity to vimentin,
CD10, PAX8, CA-IX, and were negative for AMACR, which is a typical
immunohistochemical profile of clear cell RCC. But the TSC-associated tumors were also
diffusely and strongly positive for CK7 and uniformly negative for SDHB, distinguishing
them from clear cell RCC. In addition, the diffuse membranous staining for CA-IX among
these tumors presumably reflecting activation of the hypoxia-inducible factor (HIF)
pathway, was similar to sporadic clear cell RCC; however, no deletion of chromosome 3p,
where the VHL gene resides, was detected in any neoplasms examined. Duff K et al.
similarly found neither VHL loss of heterozygosity nor other VHL gene mutation in any of
their six clear cell RCC tumors from TSC patients.(13) Together these findings indicate that
this novel tumor subset is distinct from sporadic clear cell RCC and may implicate a novel
mechanism to activate the HIF pathway in renal cell carcinogenesis in the setting of TSC.
Xp11 translocation RCC is another renal tumor in the differential diagnosis. This neoplasm
is typically composed of cells with voluminous clear to faintly eosinophilic cytoplasm,
arranged in papillary and nested structures. Nuclear labeling for TFE3 protein by
immunohistochemistry is a characteristic feature of Xp11 translocation carcinoma and was
not identified in any of the neoplasm in our series. This observation was further validated by
break-apart TFE3 FISH assay which showed no TFE3 gene translocation in these tumors.
(32) In contrary to the high nuclear grade in Xp11 translocation RCC, most tumors in our
series were intermediate nuclear grade. Psammoma bodies that are common in Xp11
translocation RCC were also not seen in any of these TSC-associated tumors.
A recently emerged entity, clear cell (tubulo) papillary RCC (CCPRCC), is recognized and
classified within the International Society of Urological Pathology Vancouver Classification
of Renal Neoplasia.(17) One of the characteristic features of CCPRCC is the apical
positioning of the low grade nuclei away from the basement membrane, arranged in a linear
fashion, which was only focally present in two tumors in our study. The CCPRCC specific
cup-shaped expression pattern of CA-IX, was not identified in any of our samples. Instead,
CA-IX was diffusely and circumferentially expressed along the cell membrane in all tumors,
resembling clear cell RCC. Furthermore, CD10 staining was diffusely positive in almost all
tumors, different from its negative to variable staining in CCPRCC.
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Papillary RCC (PRCC) tumor cells contain a small amount of clear to slightly eosinophilic
cytoplasm. The abundant clear cell cytoplasm seen in the TSC-associated papillary RCC
tumors is uncommon in PRCC. While clear cell changes and fine cytoplasmic granulations
can be occasionally seen in PRCC, these changes usually appear adjacent to hemosiderin
deposition and/or necrosis, associated with global degenerative changes.(33) Psammoma
bodies and foamy histiocytes in the fibrovascular cores, common features in PRCC, were
not seen in any of these TSC-associated tumors. Although TSC-associated papillary RCC
tumors were positive for CK7, similar to PRCC, CA-IX was also diffusely and strongly
positive, unlike typical PRCC, and AMACR expression was uniformly absent. Even though
2 tumors within this group showed gains of chromosomes 7 and 17, the typical
immunohistochemical profile of PRCC (positive for both CK7 and AMACR) is not
appreciated. The significance of gains of chromosomes 7 and 17 in these two tumors is not
understood.
Another interesting finding in this study was that this subset of renal neoplasms uniformly
lack expression of SDHB protein by immunohistochemistry. Succinate dehydrogenase
(SDH)/ mitochondrial complex II is a key respiratory enzyme, located in the inner
mitochondrial membrane that links two important pathways in energy conversion: the Krebs
tricarboxylic acid cycle and oxidative phosphorylation. It catalyzes the oxidation of
succinate to fumarate and transfers electrons to the respiratory chain ubiquinone pool.(34)
Five proteins are involved in SDH complex, SDHA, SDHB, SDHC, SDHD and SDHAF2
and are encoded by five nuclear genes, which together are known SDHx genes/SDH
complex genes. SDHA and SDHB form the catalytic core of the enzyme complex.
Inherited or somatic mutation in SDHx genes are well documented and associated with the
development of pheochromocytoma/paraganglioma (PHEO/PGL) and less commonly, with
gastrointestinal stromal tumors (GISTs). Thus, SDHx genes are regarded as tumor
suppressors. Renal cell carcinomas have rarely been reported with germline mutations in
SDHB.(19, 35-40), SDHC(41), or SDHD.(38) Together, less than 20 patients with any SDHx
gene mutations have been reported thus far, and mostly with a personal and/or family history
of PHEO/PGL.
Double hit inactivation of any component of the SDH complex results in degradation of the
SDHB subunit. Therefore, immunohistochemistry for SDHB is negative whenever there is
mutation/inactivation of SDHA, SDHB, SDHC, SDHD, or SDHAF2. Negative staining for
SDHB has been quite reliable in identifying germline mutation of the SDH B, C and D
subunits in PHEO/PGL.(42, 43) In a few paraganglioma syndrome-associated renal tumors,
negative SDHB expression was highly correlated with germline mutations in SDHB and
SDHD genes. Notably, none of the TSC patients in our cohort has a personal or family
medical history of PHEO/PGL. The absence of a family history does not formally exclude
the possibility of paraganglioma syndromes given the age related penetrance of SDHx gene
mutation and phenotypic heterogeneity. Nonetheless, our patients all met diagnostic criteria
for TSC, and had no features otherwise suggestive of the paraganglioma syndrome.
Renal tumors associated with SDHx mutations from earlier reports were classified as clear
cell, chromophobe, papillary, and unclassified RCC, or oncocytoma, without detailed
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description or illustration of morphologic features.(35-38, 44) More recent reports have
emphasized the presence of distinctive cytoplasmic inclusions in cuboidal cells with bubbly
eosinophilic cytoplasm arranged in solid nests.(17, 19, 40, 45) Importantly, we did not
observe these features in any of the SDHB-negative renal tumors reported here. It remains to
be determined if the morphological features of the renal tumors seen in these TSC patients
are seen only in TSC, or whether they will be also observed in non-TSC patients.
It is known that lack of SDH enzyme activity results in abnormal hypoxia signaling and may
trigger tumor formation. Succinate accumulates as a result of SDH dysfunction, which
consequently inhibits HIF-α prolyl hydroxylases in the cytosol, leading to stabilization and
activation of HIF-1α. HIF-1α induction may then in turn up-regulate multiple downstream
genes including CA-IX. This effect may contribute to carcinogenesis in these tumors in the
absence of VHL mutation or chromosome 3p loss, and explain the diffuse membranous IHC
labeling for CA-IX we observed.
The mechanism of loss of SDH expression in these tumors is unknown. SDHx germline
mutation seems quite unlikely since these patients had no features of SDH genetic
syndromes, and the co-existence of TSC1 or TSC2 plus SDHx germline gene mutations
would be an extremely rare event to recur in this clustered fashion by random chance. One
possible mechanism may be the acquisition of somatic mutations that inactivate one or more
of the SDHx genes, hence contributing to tumorigenesis. An alternative possibility is that the
effects of TSC1/TSC2 loss and mTORC1 activation in the particular renal epithelial cell of
origin for these tumors may somehow interrupt normal SDH expression. It will be of interest
to see if similar cases are found in sporadic, non-TSC patients, and to examine the molecular
pathology of such cases for TSC and SDH gene involvement. If germline SDHx mutation is
found in this group of tumors, it poses a possibility that two tumor suppressor genes (SDH
and TSC) may together contribute to one oncogenic event.
In this study, we additionally describe a second distinct morphologic group comprised of 15
renal epithelial neoplasms from 9 TSC patients which have features of a hybrid oncocytic/
chromophobe tumor (HOCT). HOCT tumors are most commonly described in patients with
Birt-Hogg Dubé syndrome and renal oncocytosis, with more recent reports of sporadic
cases.(46-50) It is hypothesized that renal oncocytoma and chromophobe RCC are the
extremes of the same morphologic spectrum as they both originate from the intercalated
cells of the renal collecting tubules, giving rise to neoplasms with mixed histology.(46)
Although this subset of renal epithelial neoplasms do not have a distinct immunoprofile,
their characteristic features may alert the pathologist to the possibility of a TSC-associated
renal neoplasm, in addition to those associated with Birt-Hogg Dubé syndrome.
Furthermore, correctly diagnosing this neoplasm is important as HOCTs have been
identified as a subtype of chromophobe RCC by the International Society of Urological
Pathology Vancouver Classification of Renal Neoplasia.(17)
Interestingly, renal tumors with HOCT morphology are identified in both TSC and Birt-
Hogg Dubé syndromes in which mutations in the TSC and folliculin genes, respectively,
result in downstream mTOR activation. Therefore, we hypothesize that the tumors
associated with these hereditary syndromes may acquire a similar or shared somatic
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mutation or genetic alteration, resulting in their distinct morphology. Further studies using
modalities such as genome sequencing may help to elucidate the morphologic link in these
two hereditary syndromes.
In conclusion, RCCs in TSC contain distinct morphologic features and include TSC-
associated papillary RCC and HOCT. Similar to other well-defined hereditary renal cancer
syndromes in which distinct RCC morphologic features are associated with specific
mutations, these neoplasms, in addition to angiomyolipomas may help to identify
morphologic clues to renal neoplasms associated with TSC.
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TSC Tuberous Sclerosis Complex
HOCT hybrid oncocytic/chromophobe tumor
CA-IX carbonic anhydrase IX
CK7 cytokeratin 7
SDH Succinate dehydrogenase
SDHB Succinate dehydrogenase B subunit
AMACR α-methylacyl coenzyme A racemase
LOH loss of heterozygosity
PHEO pheochromocytoma
PGL paraganglioma
VHL von Hippel-Lindau
BHD Birt-Hogg-Dubé
CCPRCC clear cell (tubulo) papillary RCC
GISTs gastrointestinal stromal tumors
Yang et al. Page 16
Am J Surg Pathol. Author manuscript; available in PMC 2015 July 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 1.
Morphologic features of TSC-associated - papillary RCC.
A, B (patient 6, tumor 11); C, D (patient 9, tumor 28); E (patient 8, tumor 22); F (patient 6,
tumor 10).
A, C: On low power, tumors predominantly displayed complex branching papillary
structure; B, D: On high power, the clear cytoplasm often contained delicate thread-like
eosinophilic strands which occasionally aggregated to form eosinophilic globules (arrow);
E: Fibrotic stroma and cystic changes were common; F: Tumor cells with clear cytoplasm
were admixed with tumor cells with fine granular eosinophilic cytoplasm.
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Figure 2.
TSC-associated papillary RCC with prominent papillary structure.
A-F (patient 5, tumor 8)
A: On low power, the main tumor nodule was surrounded by thick fibrous stroma; B: On
high power, the papillae were lined by large clear cells with fine eosinophilic cytoplasmic
thread-like strands. The nuclei oriented towards the basement membrane; C-F:
Immunohistochemical stains showed that tumor cells were strongly and diffusely positive
for CK7, CD10 and CA-IX; and negative for SDHB.
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Figure 3.
SDHB immunohistochemical staining.
A, D (patient 5, tumor 8); B, E (patient 8, tumor 27); C, F (patient 8, tumor 24); G-I: Control
tumors, G (patient 4, tumor 4); H (patient 10, tumor 30); I (patient 5, tumor 7).
A-C: Tumor cells from TSC-associated papillary RCC showed completely negative staining
for SDHB; D, E, F: Lower magnification of the tumors displayed in A, B, and C,
respectively, demonstrated strong granular cytoplasmic staining in adjacent normal renal
tubules, serving as an internal positive controls; G-I: Examples of SDHB positive renal
epithelial tumors in TSC patients, showing a staining pattern that was both cytoplasmic and
distinctly granular representing a mitochondrial pattern, was considered positive.
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Figure 4.
TSC-associated papillary RCC with prominent compact nested growth pattern showed
similar cytological and immunological features.
A-C: (patient 7, tumor 12); D-F: (patient 8, tumor 21); G-I: (patient 8, tumor 21).
A: The only focus of tumor cells exhibiting papillary architecture in background of nested
growth; B: Higher magnification of the papillary growth pattern of A (arrow); C: Higher
magnification of left upper corner of A (arrowhead), showing the compact nested
architecture consisting of clear cells with fine eosinophilic thread-like strands; D: Solid cell
nests were surrounded by loose hyalinized stroma; E: Tubules with small blunt papillae
tufted into the luminal space; F: On high power, clear cells with eosinophilic strands formed
compact nests. G-I: Immunohistochemical stains showed that tumor cells were strongly and
diffusely positive for CK7 and CA-IX, and negative for SDHB.
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Figure 5.
Histologic features of hybrid oncocytic/chromophobe tumors (HOCTs).
A: (patient 18, tumor 45); B: (patient 5, tumor 7); C: (patient 12, tumor 35); D: (patient 18,
tumor 46).
A, B: Pattern 1 with polygonal tumor cells containing abundant eosinophilic cytoplasm and
centrally placed, round nuclei with perinuclear clearing ; C: Pattern 2 with mosaicism of
areas with features characteristic of oncocytoma and chromophobe RCC. D: Nested and
tubular architecture with cells comprised of abundant eosinophilic cytoplasm typical of an
oncocytoma with more irregular, folded nuclei.
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Figure 6.
TSC-associated renal tumors with unusual features remain unclassified.
A-C: (patient 4, tumor 4, 5, 6); D-F: (patient 11, tumor 33, 32, 34); G-I: (patient 17, tumor
40).
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Table 2
Distribution by Histologic Subtypes
Tumor # of tumor # of patient
TSC-associated Papillary RCC 24 9
Hybrid oncocytic chromophobe tumor (HOCT) 15 9
Unclassified RCC 7 3
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